Mark Larkin, PhD
Mark Larkin, PhD has more than 15 years of healthcare experience advising biopharma clients on pricing, reimbursement and market access strategies, health economics, and innovative applications of technology to acquire real-world data. Mark helps clients generate evidence, conduct modelling, and develop pharmacoeconomic and commercial strategies for a compelling value proposition for reimbursement and market entry. Specifically, Mark leads the technical preparation for our clients’ dossier submissions including preparing for HTA advisory meetings, developing cost-effectiveness and budget impact models, global value dossiers, key value message development and testing, patient reported outcomes, and utility studies. Mark is a member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He has an MA in Natural Sciences and a PhD in experimental psychology.